- Home
- Posts
- 🍄 Trip Sheet: Compass Pathways (CMPS) clears Phase 3 hurdle with COMP360 psilocybin in treatment-resistant depression
🍄 Trip Sheet: Compass Pathways (CMPS) clears Phase 3 hurdle with COMP360 psilocybin in treatment-resistant depression
Clearmind (CMND) expands its AUD study to Tel Aviv, as Enveric (ENVB) reports its novel amylin-agonist antibody slashes food intake by 60% in obese mice.
Jun 26, 2025
Street Sheet Research Members Only
This content is for Street Sheet Research subscribers. Click the button below to join. You'll receive our weekly research report, monthly deep-dives, and instant access to The Street Feed.
JOIN STREET SHEET RESEARCH FOR JUST $99